SG11201805990XA - Means and methods for staging, typing and treating a cancerous disease - Google Patents

Means and methods for staging, typing and treating a cancerous disease

Info

Publication number
SG11201805990XA
SG11201805990XA SG11201805990XA SG11201805990XA SG11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA SG 11201805990X A SG11201805990X A SG 11201805990XA
Authority
SG
Singapore
Prior art keywords
international
regensburg
cancerous disease
methods
staging
Prior art date
Application number
SG11201805990XA
Other languages
English (en)
Inventor
Christoph Klein
Sebastian Scheitler
Melanie Werner-Klein
Martin Hoffmann
Isabelle Hodak
Original Assignee
Fraunhofer Ges Forschung
Univ Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Ges Forschung, Univ Regensburg filed Critical Fraunhofer Ges Forschung
Publication of SG11201805990XA publication Critical patent/SG11201805990XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201805990XA 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease SG11201805990XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (1)

Publication Number Publication Date
SG11201805990XA true SG11201805990XA (en) 2018-08-30

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805990XA SG11201805990XA (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Country Status (10)

Country Link
US (1) US11702701B2 (https=)
EP (2) EP3199641B1 (https=)
JP (1) JP2019508032A (https=)
KR (1) KR20180102674A (https=)
CN (1) CN108770360B (https=)
AU (1) AU2017211976B2 (https=)
CA (1) CA3012404A1 (https=)
ES (1) ES2905208T3 (https=)
SG (1) SG11201805990XA (https=)
WO (1) WO2017129753A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1109938T3 (da) 1998-09-18 2002-05-27 Micromet Ag DNA-amplificering af en enkelt celle
AU2002216009A1 (en) * 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
ITRM20110149A1 (it) * 2011-03-25 2012-09-26 Massimo Zollo Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione.
US20140227692A1 (en) * 2011-07-08 2014-08-14 Deborah W. Neklason Methods of detecting hereditary cancer predisposition
EP2788768A1 (en) * 2011-12-10 2014-10-15 Abbott Molecular Inc. Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma
WO2015023553A2 (en) * 2013-08-13 2015-02-19 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules
ES2730962T3 (es) 2014-02-05 2019-11-13 Fraunhofer Ges Forschung Secuenciación libre de errores de ADN

Also Published As

Publication number Publication date
CN108770360A (zh) 2018-11-06
EP3408411A1 (en) 2018-12-05
WO2017129753A8 (en) 2017-10-19
ES2905208T3 (es) 2022-04-07
EP3199641B1 (en) 2021-09-29
KR20180102674A (ko) 2018-09-17
US20190062845A1 (en) 2019-02-28
JP2019508032A (ja) 2019-03-28
US11702701B2 (en) 2023-07-18
CN108770360B (zh) 2022-06-14
EP3199641A1 (en) 2017-08-02
AU2017211976B2 (en) 2022-09-22
AU2017211976A1 (en) 2018-08-02
CA3012404A1 (en) 2017-08-03
WO2017129753A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201906553TA (en) Methods and reagents for synthesising polynucleotide molecules
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201809530PA (en) Method for recovery of phosphate
SG11201810914VA (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
SG11201810975UA (en) Method for stabilizing proteins
SG11201809413RA (en) Detection of chromosome interaction relevant to breast cancer
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201903428XA (en) Pluripotent stem cell assay
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201909882SA (en) Targeted neoepitope vectors and methods therefor
SG11201805497QA (en) Mutated truncated von willebrand factor
SG11201809996QA (en) Ribonucleic acid (rna) interactions
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer